Xencor, Inc.
http://www.xencor.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xencor, Inc.
MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
Tech Transfer Roundup: MD Anderson Working To Unlock Promise Of Tumor-Infiltrating Lymphocytes
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Immuno-Oncology’s ‘Infancy’? ‘Adolescence?’ Wherever You Peg Development, Adverse Event Reporting Needs To Mature
A common toxicity of advanced IO therapies, cytokine release syndrome needs to be better characterized as part of the groundwork for future development of the field, according to Friends of Cancer Research.
Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies